SG11202011960XA - Mesothelin and cd137 binding molecules - Google Patents

Mesothelin and cd137 binding molecules

Info

Publication number
SG11202011960XA
SG11202011960XA SG11202011960XA SG11202011960XA SG11202011960XA SG 11202011960X A SG11202011960X A SG 11202011960XA SG 11202011960X A SG11202011960X A SG 11202011960XA SG 11202011960X A SG11202011960X A SG 11202011960XA SG 11202011960X A SG11202011960X A SG 11202011960XA
Authority
SG
Singapore
Prior art keywords
mesothelin
binding molecules
molecules
binding
Prior art date
Application number
SG11202011960XA
Inventor
Jose Munoz-Olaya
Mihriban Tuna
Remi Fertin
Claire Reader
Francisca Wollerton
Neil Brewis
Original Assignee
F Star Delta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Delta Ltd filed Critical F Star Delta Ltd
Publication of SG11202011960XA publication Critical patent/SG11202011960XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202011960XA 2018-07-12 2019-07-12 Mesothelin and cd137 binding molecules SG11202011960XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1811450.4A GB201811450D0 (en) 2018-07-12 2018-07-12 Mesothelin and CD137 binding molecules
PCT/EP2019/068817 WO2020011976A1 (en) 2018-07-12 2019-07-12 Mesothelin and cd137 binding molecules

Publications (1)

Publication Number Publication Date
SG11202011960XA true SG11202011960XA (en) 2020-12-30

Family

ID=63273224

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011960XA SG11202011960XA (en) 2018-07-12 2019-07-12 Mesothelin and cd137 binding molecules

Country Status (14)

Country Link
US (1) US20210309753A1 (en)
EP (1) EP3820894A1 (en)
JP (2) JP7360441B2 (en)
KR (1) KR20210030925A (en)
CN (1) CN112437776A (en)
AR (1) AR115769A1 (en)
AU (1) AU2019303081A1 (en)
BR (1) BR112021000396A2 (en)
CA (1) CA3103173A1 (en)
GB (1) GB201811450D0 (en)
IL (1) IL280007A (en)
MX (1) MX2021000397A (en)
SG (1) SG11202011960XA (en)
WO (1) WO2020011976A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
TW201930355A (en) 2017-12-19 2019-08-01 英商Ｆ星貝塔有限公司 Binding members
CA3098374A1 (en) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
KR20220103721A (en) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Humanized Antibodies to TNF-Like Ligand 1A (TL1A) and Uses Thereof
WO2024039672A2 (en) * 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024042105A1 (en) 2022-08-26 2024-02-29 Merck Patent Gmbh Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
WO2024042104A1 (en) 2022-08-26 2024-02-29 Merck Patent Gmbh Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP2011801A1 (en) 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
JP5608091B2 (en) 2007-11-26 2014-10-15 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Anti-mesothelin antibodies and uses thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9416190B2 (en) * 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
KR101782487B1 (en) * 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 Novel Antibody Binding to Mesothelin(MSLN), and Composition Comprising the Same
ES2910365T3 (en) * 2016-04-22 2022-05-12 Alligator Bioscience Ab New bispecific polypeptides against CD137
EP3464367B1 (en) * 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CN107523546A (en) * 2016-06-20 2017-12-29 上海细胞治疗研究院 A kind of NK cells of high efficiency stable expression antibody and application thereof

Also Published As

Publication number Publication date
IL280007A (en) 2021-03-01
GB201811450D0 (en) 2018-08-29
JP7360441B2 (en) 2023-10-12
CA3103173A1 (en) 2020-01-16
WO2020011976A1 (en) 2020-01-16
AR115769A1 (en) 2021-02-24
MX2021000397A (en) 2021-05-27
US20210309753A1 (en) 2021-10-07
JP2023178323A (en) 2023-12-14
AU2019303081A1 (en) 2021-03-11
EP3820894A1 (en) 2021-05-19
KR20210030925A (en) 2021-03-18
JP2021524269A (en) 2021-09-13
BR112021000396A2 (en) 2021-04-06
TW202012448A (en) 2020-04-01
CN112437776A (en) 2021-03-02

Similar Documents

Publication Publication Date Title
SG10202107880XA (en) Mesothelin binding proteins
IL280007A (en) Mesothelin and cd137 binding molecules
IL275510A (en) Ror1-specific antigen binding molecules
IL273631A (en) Hpv-specific binding molecules
IL281901A (en) Multivalent igm- and iga-fc-based binding molecules
IL283635A (en) Binding molecules against cd3 and uses thereof
IL266464A (en) Binding molecules specific for asct2 and uses thereof
GB201702091D0 (en) Specific binding molecules
IL289415A (en) Claudin-6 binding molecules and uses thereof
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
GB201811408D0 (en) CD137 Binding Molecules
IL287555A (en) Binding molecules
IL278832A (en) Optimized gp41-binding molecules and uses thereof
HK1258317A1 (en) Binding molecules specific for asct2 and uses thereof
GB201901305D0 (en) Specific binding molecules
IL269752B (en) Fgfr3 binding molecules
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
IL288562A (en) Activating anti-gal9 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201811445D0 (en) Mesothelin and OX40 binding molecules
GB201914468D0 (en) Binding Molecules
GB201912030D0 (en) Binding molecules
GB201906870D0 (en) Binding molecules
GB201906872D0 (en) Binding molecules